Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
What the film says
For high-risk acute leukemia, a donor transplant can cure, but only if conditioning clears enough disease, and stronger conditioning damages the whole body.
The idea: deliver radiation by antibody, straight to blood cells, using a particle that travels only a few cell widths.
At Fred Hutch in Seattle, an antibody against CD45, a marker on nearly all blood and leukemia cells, is labeled with astatine-211. Astatine emits alpha particles: heavy, intensely damaging, spent within a few cells' distance. Given a week before transplant, it targets the marrow and leukemia while sparing tissue beyond. Then fludarabine, low-dose total-body irradiation, and the donor's cells follow.
A dose-finding study in adults. Brenda Sandmaier leads it. Public record; not medical advice.
Sources behind this film
Transplant curative if disease controlled; conditioning toxicity trade-off; Anti-CD45 antibody BC8 labeled with astatine-211; Alpha emitter, short path length; Day −7 infusion; fludarabine days −4 to −2; TBI; PBSC day 0 (+2 more lines)
Li Y. PLoS One, 2018
Anti-CD45 antibody BC8 labeled with astatine-211
The drug
OUTLINE: This is a dose-escalation study of 211^At-BC8-B10. Patients receive 211^At-BC8-B10 intravenously (IV) over 6-8 hours on day -7 and may receive 131^I-BC8-B10 IV on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and peripheral blood stem cell (PBSC) transplant on day 0.
Patients also receive cyclosporine orally (PO) or IV every 12 hours on days -3 to 56 and then tapered to day 180 (for patients with related donors), or continuing to day 96 and then tapered to day 150 (for patients with unrelated donors).
The study
This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia.
Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before donor stem cell transplant.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.